Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $102.5. The company shows strong revenue growth but faces challenges in profitability and returns.
October 04, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has received a mix of bullish and somewhat bullish ratings from analysts, with an increased average price target of $102.5. The company shows strong revenue growth but struggles with profitability and returns.
The majority of analysts have a somewhat bullish outlook on ITCI, with an increased average price target, indicating positive sentiment. The company's strong revenue growth supports this view, although profitability challenges may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100